Calidi Biotherapeutics, Inc.
CLDI· NYSE
Who holds Calidi Biotherapeutics, Inc., from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 114.6K | +81.8% | $19.5K | 0% | Aug 12, 2026 |
| HighTower Advisors, LLC | 83.5K | ±0% |
| $14.2K |
| 0% |
| Aug 5, 2026 |
| Jane Street Group, LLC | 54.3K | +56.0% | $9.2K | 0% | Aug 14, 2026 |
| Independent Advisor Alliance | 45K | New | $7.7K | 0.1% | Aug 12, 2026 |
| RS Crum Inc. | 43.2K | +7.4% | $7.4K | 0.1% | Aug 10, 2026 |
| Arax Advisory Partners | 37.3K | ±0% | $6.3K | 0% | Aug 10, 2026 |
| Private Advisor Group, LLC | 30K | New | $5.1K | 0% | Jul 27, 2026 |
| Vanguard Capital Management LLC | 25.5K | ±0% | $4.3K | 0% | Aug 13, 2026 |
| Belpointe Asset Management LLC | 19.9K | ±0% | $3.4K | 0.1% | Jul 31, 2026 |
| Northern Trust Corp | 17.8K | ±0% | $3K | 0% | Aug 13, 2026 |
| Morgan Stanley | 13.2K | +39.9% | $2.3K | 0% | Aug 13, 2026 |
| RFG Advisory, LLC | 12K | New | $2K | 0% | Jul 15, 2026 |
| Farther Finance Advisors, LLC | 10K | ±0% | $1.7K | 0% | Jul 17, 2026 |
| UBS Group AG | 7.9K | New | $1.3K | 0% | Aug 13, 2026 |
| Citigroup Inc | 4.6K | +32,714.3% | $781 | 0% | Aug 3, 2026 |
| Osaic Holdings, Inc. | 2.7K | +25.8% | $450 | 0% | Aug 14, 2026 |
| Tower Research Capital LLC (TRC) | 1.4K | ±0% | $237 | 0% | Aug 11, 2026 |
| Finepoint Capital LP | 1K | ±0% | $177 | 0% | Aug 13, 2026 |
| Highbridge Capital Management LLC | 1K | ±0% | $177 | 0% | Aug 14, 2026 |
| SBI Securities Co., Ltd. | 375 | +226.1% | $64 | 0% | Jul 23, 2026 |
| Tradewinds Capital Management, LLC | 101 | ±0% | $18 | 0% | Jul 24, 2026 |
| Reyes Financial Architecture, Inc. | 100 | ±0% | $17 | 0% | Jul 17, 2026 |
| Evermay Wealth Management LLC | 1 | ±0% | $1 | 0% | Jul 27, 2026 |